These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37301125)

  • 1. The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer.
    Meng S; Li M; Qin L; Lv J; Wu D; Zheng D; Jia H; Chen D; Wu Q; Long Y; Tang Z; Tang Y; Yang L; Yao Y; Luo X; Li P
    Int Immunopharmacol; 2023 Aug; 121():110402. PubMed ID: 37301125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The Construction of ROR1 Targeting Chimeric Antigen Receptor Modified T Cells and Its Killing Effect for ROR1-positive Tumor Cells].
    Chen Y; Mo ZM; Qin DY; Guo FC; Liao XL; Hu M; Chen Q; Wang YS
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Mar; 50(2):145-151. PubMed ID: 31106530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
    Hudecek M; Lupo-Stanghellini MT; Kosasih PL; Sommermeyer D; Jensen MC; Rader C; Riddell SR
    Clin Cancer Res; 2013 Jun; 19(12):3153-64. PubMed ID: 23620405
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Stüber T; Monjezi R; Wallstabe L; Kühnemundt J; Nietzer SL; Dandekar G; Wöckel A; Einsele H; Wischhusen J; Hudecek M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.
    Srivastava S; Salter AI; Liggitt D; Yechan-Gunja S; Sarvothama M; Cooper K; Smythe KS; Dudakov JA; Pierce RH; Rader C; Riddell SR
    Cancer Cell; 2019 Mar; 35(3):489-503.e8. PubMed ID: 30889382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.
    Berger C; Sommermeyer D; Hudecek M; Berger M; Balakrishnan A; Paszkiewicz PJ; Kosasih PL; Rader C; Riddell SR
    Cancer Immunol Res; 2015 Feb; 3(2):206-16. PubMed ID: 25355068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
    Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
    Harrasser M; Gohil SH; Lau H; Della Peruta M; Muczynski V; Patel D; Miranda E; Grigoriadis K; Grigoriadis A; Granger D; Evans R; Nathwani AC
    Breast Cancer Res; 2022 Jun; 24(1):39. PubMed ID: 35659040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
    Huang X; Park H; Greene J; Pao J; Mulvey E; Zhou SX; Albert CM; Moy F; Sachdev D; Yee D; Rader C; Hamby CV; Loeb DM; Cairo MS; Zhou X
    PLoS One; 2015; 10(7):e0133152. PubMed ID: 26173023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.
    Deniger DC; Yu J; Huls MH; Figliola MJ; Mi T; Maiti SN; Widhopf GF; Hurton LV; Thokala R; Singh H; Olivares S; Champlin RE; Wierda WG; Kipps TJ; Cooper LJ
    PLoS One; 2015; 10(6):e0128151. PubMed ID: 26030772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
    Srivastava S; Furlan SN; Jaeger-Ruckstuhl CA; Sarvothama M; Berger C; Smythe KS; Garrison SM; Specht JM; Lee SM; Amezquita RA; Voillet V; Muhunthan V; Yechan-Gunja S; Pillai SPS; Rader C; Houghton AM; Pierce RH; Gottardo R; Maloney DG; Riddell SR
    Cancer Cell; 2021 Feb; 39(2):193-208.e10. PubMed ID: 33357452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in CAR-T cells therapy for colorectal cancer.
    Qin X; Wu F; Chen C; Li Q
    Front Immunol; 2022; 13():904137. PubMed ID: 36238297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
    Hudecek M; Schmitt TM; Baskar S; Lupo-Stanghellini MT; Nishida T; Yamamoto TN; Bleakley M; Turtle CJ; Chang WC; Greisman HA; Wood B; Maloney DG; Jensen MC; Rader C; Riddell SR
    Blood; 2010 Nov; 116(22):4532-41. PubMed ID: 20702778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models.
    Wallstabe L; Göttlich C; Nelke LC; Kühnemundt J; Schwarz T; Nerreter T; Einsele H; Walles H; Dandekar G; Nietzer SL; Hudecek M
    JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31415244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROR1-targeting switchable CAR-T cells for cancer therapy.
    Peng H; Nerreter T; Mestermann K; Wachter J; Chang J; Hudecek M; Rader C
    Oncogene; 2022 Aug; 41(34):4104-4114. PubMed ID: 35859167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer.
    Li M; Li S; Zhao R; Lv J; Zheng D; Qin L; Li S; Wu Q; Long Y; Tang Z; Tang YL; Yang L; Yao Y; Luo X; Li P
    Clin Exp Med; 2023 Oct; 23(6):2409-2419. PubMed ID: 36495368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.
    Balakrishnan A; Goodpaster T; Randolph-Habecker J; Hoffstrom BG; Jalikis FG; Koch LK; Berger C; Kosasih PL; Rajan A; Sommermeyer D; Porter PL; Riddell SR
    Clin Cancer Res; 2017 Jun; 23(12):3061-3071. PubMed ID: 27852699
    [No Abstract]   [Full Text] [Related]  

  • 20. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
    Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
    Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.